J C Byrd

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
  2. ncbi request reprint Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance
    Rajat Bannerji
    Division of Hematology Oncology, Starling Loving Hall, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 21:1466-71. 2003
  3. ncbi request reprint Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab
    John C Byrd
    The Division of Hematology Oncology, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 63:36-8. 2003
  4. ncbi request reprint Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 101:6-14. 2003
  5. ncbi request reprint Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
    John C Byrd
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, B302A Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1240, USA
    J Clin Oncol 22:1087-94. 2004
  6. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia: old and new therapies
    John C Byrd
    Division of Hematology and Oncology, The Ohio State University, The Arthur James Comprehensive Cancer Center, Columbus, OH 43210, USA
    Semin Oncol 33:210-9. 2006
  7. ncbi request reprint KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
    John C Byrd
    Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 101:4547-50. 2003
  8. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
  9. ncbi request reprint UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism
    J C Byrd
    Division of Hematology Oncology, Walter Reed Army Medical Center, Washington, DC, USA
    Exp Hematol 29:703-8. 2001
  10. ncbi request reprint A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
    John C Byrd
    Department of Internal Medicine, Division of Hematology Oncology, Starling Loving Hall, Rm 302, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:959-67. 2005

Detail Information

Publications130 found, 100 shown here

  1. ncbi request reprint Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    ....
  2. ncbi request reprint Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance
    Rajat Bannerji
    Division of Hematology Oncology, Starling Loving Hall, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 21:1466-71. 2003
    ..Here we examine pretreatment biologic features that promote resistance to apoptosis and CDC in CLL patients and correlate it with clinical outcome to rituximab-based therapy...
  3. ncbi request reprint Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab
    John C Byrd
    The Division of Hematology Oncology, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 63:36-8. 2003
    ..These data suggest that interphase cytogenetics in CLL may be predictive of a response to rituximab therapy and provide support for additional studies validating risk-adapted therapy in this disease...
  4. ncbi request reprint Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 101:6-14. 2003
    ..Rituximab administered concurrently with fludarabine in previously untreated CLL patients demonstrates marked clinical efficacy and acceptable toxicity. Phase 3 studies using this combination approach for patients with CLL are warranted...
  5. ncbi request reprint Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461
    John C Byrd
    Division of Hematology and Oncology and the Comprehensive Cancer Center, The Ohio State University, B302A Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210 1240, USA
    J Clin Oncol 22:1087-94. 2004
    ..To study the impact of repetitive (three to four courses) versus a single course of high-dose cytarabine (HDAC) consolidation therapy on outcome of patients with acute myeloid leukemia (AML) and inv(16)(p13q22) or t(16;16)(p13;q22)...
  6. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia: old and new therapies
    John C Byrd
    Division of Hematology and Oncology, The Ohio State University, The Arthur James Comprehensive Cancer Center, Columbus, OH 43210, USA
    Semin Oncol 33:210-9. 2006
    ..We discuss selection of therapy for the relapsed patient using risk stratification and the role of clinical research in continuing to pursue therapeutic advances against CLL...
  7. ncbi request reprint KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
    John C Byrd
    Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 101:4547-50. 2003
    ..These data demonstrate KRN5500 has significant in vitro activity against human CLL cells, thus providing support for introduction of this agent into clinical trials for patients with CLL...
  8. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
    ..We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration...
  9. ncbi request reprint UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism
    J C Byrd
    Division of Hematology Oncology, Walter Reed Army Medical Center, Washington, DC, USA
    Exp Hematol 29:703-8. 2001
    ..We sought to study the in vitro activity of UCN-01 against human chronic lymphocytic leukemia (CLL) cells and potential mechanisms of action for inducing this cytotoxicity...
  10. ncbi request reprint A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
    John C Byrd
    Department of Internal Medicine, Division of Hematology Oncology, Starling Loving Hall, Rm 302, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:959-67. 2005
    ..Future studies with depsipeptide should examine alternative administration schedules...
  11. pmc A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
    J A Woyach
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leukemia 23:912-8. 2009
    ..The combination of etanercept and thrice weekly rituximab produces durable remissions in non-del(17p13.1) CLL patients and is well tolerated...
  12. ncbi request reprint Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    J C Byrd
    Division of Hematology Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, USA
    J Clin Oncol 19:2153-64. 2001
    ..This study sought to decrease the initial toxicity and optimize the pharmacokinetics with an alternative treatment schedule...
  13. ncbi request reprint Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
    L Alinari
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Oncogene 26:3644-53. 2007
    ..Additional studies detailing the mechanism of action of alemtuzumab as well as new strategies for prevention of opportunistic infections will aid in the future therapeutic development of this agent...
  14. ncbi request reprint Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia
    T S Lin
    The Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Leukemia 19:1207-10. 2005
    ..Filgrastrim should not be administered prophylactically during alemtuzumab therapy outside clinical trials...
  15. pmc Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    K A Blum
    Division of Hematology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
    Leukemia 25:1444-51. 2011
    ..TLS does not appear to be predictive of response or improved PFS in patients receiving flavopiridol...
  16. pmc Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2637-45. 2009
    ..These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity...
  17. ncbi request reprint Combination therapy with etanercept and rituximab in relapsed CLL/SLL
    J A Woyach
    The Ohio State University, Columbus, OH
    J Clin Oncol 26:7065. 2008
    ..We examined whether disruption of TNF-a signaling by etanercept would improve response duration to rituximab in CLL...
  18. ncbi request reprint Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)
    T S Lin
    The Ohio State University, Columbus, OH
    J Clin Oncol 26:7007. 2008
    ..We report a phase II trial to confirm these findings...
  19. ncbi request reprint Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells
    M I Klisovic
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leukemia 17:350-8. 2003
    ....
  20. ncbi request reprint Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered
    J C Byrd
    Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Clin Oncol 17:3767-75. 1999
    ..To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute myeloid leukemia (AML) who have the t(8;21)(q22;q22) karyotype...
  21. ncbi request reprint Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells
    J K Waselenko
    Hematology/Oncology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Leuk Lymphoma 42:1049-53. 2001
    ..3%; 95% CI+/-11.2). These data provide evidence that CAI can induce apoptosis in human CLL cells in vitro at drug concentrations attainable in vivo. These findings justify phase II studies of CAI in patients with B-CLL...
  22. ncbi request reprint Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL
    J M Flynn
    The Ohio State University, Columbus, OH The Ohio State University Comprehensive Cancer Center and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH Merck and Co, Inc, Kenilworth, NJ
    J Clin Oncol 29:6623. 2011
    ..6623 Background: Dinaciclib is a potent and selective inhibitor of CDKs 1, 2, 5, and 9, with anti-CLL activity in ex vivo assays...
  23. pmc Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma
    R Mani
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Vet Comp Oncol . 2016
    ..These studies provide a rational basis for the use of spontaneous lymphoma in pet dogs as a preclinical large animal model for the development of OSU-2S as small molecule for treating people and dogs with lymphoma...
  24. ncbi request reprint Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461
    C D Bloomfield
    The Ohio State University, Columbus, OH, USA
    Ann Hematol 83:S84-5. 2004
  25. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  26. ncbi request reprint Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
    Syed Rehan A Hussain
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 13:2144-50. 2007
    ..Mcl-1 has also been reported to mediate resistance to rituximab in CLL. We therefore investigated whether direct reduction of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab...
  27. pmc Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  28. pmc Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
    Thomas S Lin
    The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:4500-6. 2010
    ..To determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia...
  29. ncbi request reprint Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dos
    W G Blum
    The Ohio State University, Columbus, OH
    J Clin Oncol 26:7075. 2008
    ..7075 Background: L is active in myelodysplastic syndromes and myeloma and may also have activity in AL or CLL...
  30. ncbi request reprint The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
    D M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus OH, USA
    Leukemia 18:1207-14. 2004
    ..Similar to many other therapeutic targets, MS-275-mediated apoptosis is reduced by overexpression of Bcl-2, justifying strategies to combine HDAC inhibitors with Bcl-2 antagonists...
  31. doi request reprint Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
    M S Czuczman
    Department of Medicine, Lymphoma Myeloma Section, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Ann Oncol 23:2356-62. 2012
    ..This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL)...
  32. ncbi request reprint A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211
    J C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leukemia 17:323-7. 2003
    ..Cladribine has modest clinical activity and considerable toxicity in a very selected group of patients with fludarabine-refractory CLL lacking pre-treatment neutropenia and thrombocytopenia...
  33. pmc Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
    K A Blum
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Ann Oncol 21:2246-54. 2010
    ....
  34. ncbi request reprint Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance
    J C Byrd
    Division of Hematology Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Clin Oncol 17:791-5. 1999
    ..Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood...
  35. ncbi request reprint Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism
    A P Mone
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leukemia 20:272-9. 2006
    ..Furthermore, the differential direct cytotoxic effect suggests that CD52 directed antibodies could possibly be engineered to more specifically target CLL cells...
  36. pmc Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 115:489-95. 2010
    ..A randomized trial comparing lumiliximab plus FCR with FCR alone is underway to define the benefit of this combination in relapsed CLL. This trial was registered at clinicaltrials.gov as NCT00103558...
  37. ncbi request reprint Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:437-43. 2006
    ..1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy...
  38. pmc Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 27:6012-8. 2009
    ..Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated...
  39. pmc Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:399-404. 2007
    ..Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases...
  40. pmc Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Kristie A Blum
    Division of Hematology Oncology, Ohio State University Medical Center, Columbus, OH 43210, USA
    Br J Haematol 147:507-14. 2009
    ..Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs...
  41. ncbi request reprint Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Leuk Lymphoma 50:1589-96. 2009
    ..The administration of alemtuzumab as consolidation therapy following an abbreviated fludarabine induction is feasible but requires close monitoring for CMV infection and other infectious events...
  42. pmc Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  43. pmc Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:418-23. 2010
    ..We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR...
  44. ncbi request reprint A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL
    L Andritsos
    The Ohio State University, Columbus, OH Cornell University, New York, NY Sarah Cannon Research Institute, Nashville, TN University of Alabama at Birmingham, Birmingham, AL Trubion Pharmaceuticals Inc, Seattle, WA
    J Clin Oncol 27:3017. 2009
    ..A phase I study with TRU-016 was initiated based upon these data...
  45. ncbi request reprint Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older
    W G Blum
    The Ohio State University, Columbus, OH
    J Clin Oncol 27:7010. 2009
    ..2007)...
  46. ncbi request reprint Second primary malignancies after chronic lymphocytic leukemia
    J M Flynn
    The Ohio State University, Columbus, OH
    J Clin Oncol 26:9632. 2008
    ..We sought to determine population-based estimates of the risk for secondary neoplasia according to age, surveillance time, gender and year of diagnosis...
  47. ncbi request reprint High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
    S S Farag
    Hematologic Malignancies Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Bone Marrow Transplant 35:653-61. 2005
    ..03) compared to BuCy2, resulting in similar survival. Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients...
  48. ncbi request reprint Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity
    J C Byrd
    Division of Hematology Oncology, Walter Reed Army Medical Center, Washington, DC, USA
    Ann Oncol 10:1525-7. 1999
    ..These data suggest that rituximab has clinical activity in heavily pre-treated patients with Waldenstrom's macroglobulinemia. Based on these data, clinical studies of Rituximab in previously untreated and treated WM appear indicated...
  49. ncbi request reprint Flavopiridol in the treatment of chronic lymphocytic leukemia
    Beth A Christian
    Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Oncol 19:573-8. 2007
    ..This review focuses on a novel dosing regimen that has achieved significant clinical activity in relapsed, poor-risk chronic lymphocytic leukemia...
  50. doi request reprint A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 14:569-78. 2008
    ..We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo...
  51. ncbi request reprint Atypical lymphocytic lobular panniculitis
    Cynthia M Magro
    Department of Pathology, St John Medical Center and Regional Medical Laboratories, Tulsa, OK, USA
    J Cutan Pathol 31:300-6. 2004
    ..Although subcutaneous T-cell lymphoma (SCTCL) is considered an aggressive form of lymphoma, some patients manifest a long waxing and waning phase unaccompanied by constitutional symptoms...
  52. pmc Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
    Syed Rehan A Hussain
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:3190-9. 2008
    ..These observations suggest that in CLL and 697 cells, flavopiridol mediates its cytotoxic effects via induction of the mitochondrial permeability transition and changes in intracellular calcium...
  53. ncbi request reprint Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
    Gerard Lozanski
    Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Blood 103:3278-81. 2004
    ..The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions...
  54. pmc Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:349-56. 2009
    ..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted...
  55. ncbi request reprint Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
    Andrew P Mone
    Division of Hematology Oncology, The Ohio State University, Columbus 43210, USA
    Blood 103:1846-54. 2004
    ..These data suggest that Hu1D10 ligation in CLL cells induces death and survival signals for which combination therapies may be designed to greatly enhance efficiency of both Hu1D10 and other class II antibodies in development...
  56. doi request reprint Flavopiridol in chronic lymphocytic leukemia: a concise review
    Beth A Christian
    Division of Hematology Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Lymphoma Myeloma 9:S179-85. 2009
    ..Several other investigational CDKi in preclinical and early clinical development are briefly discussed in this review...
  57. doi request reprint Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
    Thomas S Lin
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:1977-82. 2009
    ..Therefore, this schedule of administration achieved MGd uptake into primary tumor cells in vivo, but clinical activity was modest...
  58. pmc Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
    ..Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment...
  59. ncbi request reprint Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
    ..The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years)...
  60. pmc Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 150:189-95. 2010
    ..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL...
  61. pmc A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application
    Kenneth K Chan
    The Ohio State University, Columbus, 43210, USA
    AAPS J 12:556-68. 2010
    ..These concentrations are in a range that shows biological activities. We conclude that this method provides a general and valuable tool for the pharmacologic study and clinical development of synthetic miRNAs...
  62. ncbi request reprint Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population
    Jeremy G Perkins
    Department of Medicine, Walter Reed Army Medical Center, Washington, D C, USA
    Cancer 94:2033-9. 2002
    ..Little data exist regarding the frequency of infections in this population treated with noninvestigational best supportive care therapies...
  63. ncbi request reprint The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
    John C Byrd
    Division of Hematology Oncology, The Ohio State University, B302 Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA
    Blood 99:1038-43. 2002
    ....
  64. ncbi request reprint Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
    John C Byrd
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 13:4448-55. 2007
    ..We conducted a phase 1, dose escalation and schedule optimization study of the primatized anti-CD23 antibody, lumiliximab, in patients with previously treated and refractory CLL...
  65. pmc Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
    Amy J Johnson
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:1334-8. 2006
    ....
  66. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  67. ncbi request reprint High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation
    William Blum
    Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University Hospitals, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:61-7. 2006
    ....
  68. ncbi request reprint Adult Burkitt leukemia and lymphoma
    Kristie A Blum
    Division of Hematology and Oncology, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, A437 Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 104:3009-20. 2004
    ....
  69. ncbi request reprint Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:49-53. 2005
    ..Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine...
  70. pmc Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases
    Po Hsien Huang
    Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Mol Pharmacol 79:197-206. 2011
    ..These data suggest a cross-talk mechanism between HDACs and H3K4 demethylases via Sp1-mediated transcriptional regulation, which underlies the complexity of the functional role of HDACs in the regulation of histone modifications...
  71. ncbi request reprint Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM
    J C Byrd
    The Ohio State University, Columbus, OH Trubion Pharmaceuticals Inc, Seattle, WA
    J Clin Oncol 27:3035. 2009
    ..A novel CD37SMIP was previously demonstrated to mediate superior direct apoptosis and NK-cell mediated killing of chronic lymphocytic leukemia (CLL) and other B-cell malignancies...
  72. ncbi request reprint Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study
    J C Byrd
    Ohio State University, Columbus, OH University of California San Diego, San Diego, CA Sarah Cannon Cancer Institute, Nashville, TN University of Alabama Birmingham, Birmingham, AL University of California San Diego Moores Cancer Center, San Diego, CA Biogen Idec, San Diego, CA University of Texas M D Anderson Cancer Center, Houston, CA
    J Clin Oncol 26:7003. 2008
    ..In addition, CD23 receptor occupancy on BCLL cells with L + FCR and possible effects of elevated serum CD23 were evaluated...
  73. ncbi request reprint Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia
    S E Coutre
    Stanford Cancer Center, Stanford, CA The Ohio State University Comprehensive Cancer Center and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH Weill Cornell Medical College, New York, NY Dana Farber Cancer Institute, Boston, MA The Ohio State University, Columbus, OH Washington University School of Medicine, St Louis, MO Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN University of Wisconsin, Madison, WI Oregon Health and Science University, Portland, OR Calistoga Pharmaceuticals, Seattle, WA
    J Clin Oncol 29:6631. 2011
    ..Expression of the PI3K p110δ isoform (PI3Kδ) is restricted to cells of hematopoietic origin. CAL-101 is an isoform-selective inhibitor of PI3Kδ that induces apoptosis of chronic lymphocytic leukemia (CLL) cells...
  74. pmc Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
    K A Rogers
    Division of Hematology, The Ohio State University, Columbus, OH, USA
    Leukemia 30:346-50. 2016
    ..We found that ibrutinib treatment is associated with a low rate of treatment-emergent AIC. Patients with an existing AIC have been successfully treated with ibrutinib and subsequently discontinued AIC therapy. ..
  75. ncbi request reprint Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma
    D J Vick
    Department of Pathology, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Vox Sang 74:122-6. 1998
    ..We report a patient with small lymphocytic lymphoma (phenotypic CLL) who developed symptomatic anemia 3 weeks after her fifth cycle of fludarabine, a T cell immunosuppressant...
  76. ncbi request reprint Antibody therapy of acute and chronic leukemias
    S R Cataland
    Division of Hematology-Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Curr Pharm Biotechnol 2:357-67. 2001
    ..In the following review we will discuss the clinical development and potential roles of monoclonal antibodies in the treatment of both acute and chronic leukemias...
  77. ncbi request reprint Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
    ..These results suggest a novel mechanism for gene silencing mediated by RUNX1/MTG8 and support the combination of HDAC and DNMT inhibitors as a novel therapeutic approach for t(8;21) AML...
  78. ncbi request reprint Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
    Michael R Grever
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Best Pract Res Clin Haematol 20:545-56. 2007
    ..1) is a major focus of several investigators. Selection of therapy based on high-risk genomic features represents an appropriate treatment approach supported by currently available published data...
  79. ncbi request reprint Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein
    Jennifer L Aron
    Department of Internal Medicine, The Division of Hematology Oncology, The Ohio State University, Columbus, USA
    Blood 102:652-8. 2003
    ..These data suggest use of histone H3 and H4 acetylation, inhibition of histone deacetylase, and down-regulation of FLIP as pharmacodynamic end points for further evaluation of this drug in patients...
  80. pmc CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
    Farrukh T Awan
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:1204-13. 2010
    ..These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies...
  81. pmc A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    The Ohio State University, B401, Starling Loving Hall, 320 W 10th av, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 66:151-8. 2010
    ..A phase I study to determine the maximum tolerated dose (MTD) of bortezomib (B) when combined with weekly paclitaxel in patients with advanced solid tumors...
  82. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  83. pmc Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
    Lapo Alinari
    Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    MAbs 1:31-40. 2009
    ....
  84. pmc FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA
    Blood 111:275-84. 2008
    ..These results provide the first evidence for the potential use of FTY720 as a therapeutic agent in a variety of B-cell malignancies, including CLL...
  85. doi request reprint Rituximab in chronic lymphocytic leukemia
    Samantha M Jaglowski
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH
    Semin Hematol 47:156-69. 2010
    ..Future efforts focusing on novel combination-based strategies will be required to fully appreciate the benefit of this therapy in CLL...
  86. pmc The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 113:4656-66. 2009
    ..These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias...
  87. pmc Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
    Farrukh T Awan
    The Ohio State University, Columbus, USA
    Blood 113:535-7. 2009
    ..Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)...
  88. pmc A novel liposomal formulation of flavopiridol
    Xiaojuan Yang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Int J Pharm 365:170-4. 2009
    ..Further preclinical studies are warranted to define the toxicity and therapeutic efficacy of this novel formulation...
  89. pmc 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition
    Erin Hertlein
    Department of Internal Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center at The Ohio State University, 410West 12th Avenue, Columbus, OH 43210, USA
    Blood 116:45-53. 2010
    ..Therefore, the effect of 17-DMAG on NF-kappaB signaling pathways represents a novel therapy warranting further clinical pursuit in this and other B-cell lymphoproliferative disorders...
  90. ncbi request reprint Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population...
  91. pmc The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
    Samantha M Jaglowski
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 116:3705-14. 2010
    ..In addition, recent efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative non-chemotherapy-based treatment approaches...
  92. pmc Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
    Leslie A Andritsos
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 26:2519-25. 2008
    ..Herein, we highlight life-threatening tumor flare when higher doses of lenalidomide are administered to patients with CLL and provide a potential mechanism for its occurrence...
  93. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  94. ncbi request reprint Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
    J C Byrd
    The Ohio State University Comprehensive Cancer Center and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH The Ohio State University, Columbus, OH University of Texas M D Anderson Cancer Center, Houston, TX Stanford Cancer Center, Stanford, CA Willamette Valley Cancer Institute, US Oncology, Springfield, OR Weill Cornell Medical College, New York, NY Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN University of Vermont College of Medicine Fletcher Allen Health Care, Burlington, VT US Oncology Research, LLC, The Woodlands, TX Texas Oncology, Tyler, TX Pharmacyclics, Sunnyvale, CA
    J Clin Oncol 29:6508. 2011
    ..We report interim results of a large Phase Ib/II trial of P in CLL/SLL...
  95. ncbi request reprint Novel jumping translocations (JT) associated with genetic instability and aggressive disease in chronic lymphocytic leukemia (CLL)
    C Miller
    The Ohio State University, Columbus, OH The Ohio State University Comprehensive Cancer Center and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH
    J Clin Oncol 29:6533. 2011
    ..Their presence is considered to indicate genetic instability and an aggressive disease state. While JT has been reported in hematologic tumors, there have been no reports of their occurrence in CLL...
  96. ncbi request reprint Concurrent pernicious anemia and myelodysplastic syndrome
    J J Drabick
    Hematology Oncology Service, Walter Reed Army Medical Center, Washington, DC 20307 5000, USA
    Ann Hematol 80:243-5. 2001
    ..Whether acquired karyotype abnormalities from the MA were related to the MDS and subsequent myeloid leukemia in this woman is a speculative but intriguing consideration that is discussed...
  97. ncbi request reprint Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia
    R B Weiss
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Clin Oncol 16:1885-9. 1998
    ..A report of the clinical features, treatment, and outcome of patients who developed hemolytic anemia (HA) temporally associated with fludarabine (Fludara; Berlex Laboratories, Richmond, CA) therapy for chronic lymphocytic leukemia (CLL)...
  98. pmc Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
    Rebecca B Klisovic
    Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 14:3889-95. 2008
    ....
  99. pmc Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease
    Jennifer A Woyach
    The Ohio State University, Columbus, USA
    Br J Haematol 148:754-9. 2010
    ..2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing...
  100. ncbi request reprint A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia
    F T Awan
    Georgia Health Sciences University, Augusta, GA Fred Hutchinson Cancer Research Center, Seattle, WA John Theurer Cancer Center, Hackensack, NJ Rocky Mountain Cancer Center, US Oncology, Denver, CO SUNY Upstate Medical University, Syracuse, NY Emergent Biosolutions, Inc, Seattle, WA The Ohio State University Comprehensive Cancer Center and Arthur G James Cancer Hospital and Solove Research Institute, Columbus, OH Division of Haematology, Department of Medicine, Medical University of Vienna, Vienna, Austria
    J Clin Oncol 29:e13053. 2011
    ..A dose escalating phase I study in 57 patients with TRU-016 was recently completed. The highest dose tested was 20 mg/kg and a MTD was not reached...
  101. pmc Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
    J Flynn
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center at The Ohio State University, Columbus, OH, USA
    Leukemia 29:1524-9. 2015
    ..1) with a median progression-free survival of 481 days. Dinaciclib is clinically active in relapsed CLL including those patients with high risk del(17)(p13.1) disease and warrants future study...

Research Grants4

  1. A PHASE 1 Study of HuD10 IN CLL/SLL PATIENTS
    John Byrd; Fiscal Year: 2002
    ..These laboratory studies combined with clinical data derived from this trial will form the basis for future phase II development of this agent in CLL/SLL. ..
  2. DEPSIPEPTIDE: A NOVEL HISTONE DEACYTLASE INHIBITOR IN L
    John Byrd; Fiscal Year: 2003
    ..The clinical and laboratory results of this trial will provide pharmacokinetic and pharmacodynamic information for additional correlative efforts in both single agent phase II and combination phase I studies. ..
  3. Epigenetic Targeted Therapy for Chronic Lymphocytic Leu*
    John Byrd; Fiscal Year: 2005
    ..abstract_text> ..
  4. Molecular Markers: Response to Chemo-immunotherapy in C*
    John Byrd; Fiscal Year: 2005
    ..Such therapy would potentially administer different types of chemoimmunotherapy based upon the presence or absence of IgVH mutational status and p53 dysfunction. ..